Understanding HoLEP - Advances in Prostate Treatment - Dr Jeevagan Murugesan

Published Date: 01 Mar 2023

Benign prostatic hyperplasia (BPH) is a condition in which the prostate gland enlarges, causing problems or obstruction in urination...

Read Full News

Latest News

US Judge Rejects Bayer Bid to Block Johnson & Johnson Prostate Cancer Drug Claims

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

This Test Could Predict Incontinence Risk After HoLEP

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

Smartphone App Helps Delay Ejaculation

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

US FDA Approves Lantheus' New Prostate Cancer Imaging Formulation

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Will a Smart Toilet Turn the Home Into a Diagnostic Center?

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Bayer Sues Johnson & Johnson Over Claim That Prostate Cancer Drug Cuts Risk Of Death

Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely advertising that its rival multibillion-dollar drug cuts the ⁠risk of death from prostate...

Todays Updates

Baveno Criteria May Reduce Endoscopy Burden in Cirrhosis

The Baveno VI criteria show high sensitivity for ruling out clinically significant portal hypertension and high-risk varices in patients with cirrhosis.

Todays Updates

Baveno Criteria May Reduce Endoscopy Burden in Cirrhosis

The Baveno VI criteria show high sensitivity for ruling out clinically significant portal hypertension and high-risk varices in patients with cirrhosis.

Latest News

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely advertising that its rival multibillion-dollar drug cuts the ⁠risk of death from prostate...

News All Time

Nivolumab Plus Chemotherapy in First Line Approved for Bladder Cancer.

Combination decreased death risk by 22%.

King Charles III's Operation; COVID-19 Timeline Under Question; FDA Approvals Reach Record High.

The staff of MedPage Today has compiled health news and commentary from around the web.

Noninvasive Treatment Effective in Bladder Cancer That Is Not Muscle-Invasive.

An investigational intrusive solution produced a 79% complete response rate.

For Prostate Cancer at Intermediate Risk, SBRT Is Not Less Effective Than Conventional RT.

Similar results are obtained from treatment lasting one to two weeks as compared to therapy lasting up to seven and a half weeks.

The new first-line standard for advanced bladder cancer was produced by a landmark trial.

When compared to chemotherapy, enfortumab vedotin-pembrolizumab doubles OS and PFS.

Should Patients With Advanced Prostate Cancer Get Off the Active Surveillance Train?

Clearly defined rules are needed.

Even in those with HIV, a single dose of antibiotics was able to cure early syphilis.

In a randomized trial, one dosage showed no worse results than a triple-dose regimen.

Removing Cancer Survivors From Oncologic Treatment.

A new approach to care is required.

Cabazitaxel Lower-Dose Schedule Is Viable for Elderly Patients With mCRPC.

Neutropenia of grade three or above, with a twelve-fold reduction in neutropenic consequences.

AR-Pathway Inhibitor Switch for mCRPC is Superseded by Radionuclide Therapy.

With 177Lu-PSMA-617, the time to radiographic progression was doubled.

An RCT Supports HIF-2a Inhibition in Advanced RCC.

Belzutifan outperforms everolimus in the event of immunotherapy-TKI failure.

Finding New Routes to Improve Renal Cell Carcinoma Outcomes.

It is necessary to intervene at several stages of the cancer immunity cycle in order to build on recent successes.

CAR T-Cell Therapy for Renal Cell Carcinoma: "We're Not There Yet".

Possibility of standard of care following current therapies, but significant barriers still need to be overcome.

In severe cases of renal cell carcinoma, tyrosine kinase inhibitor activity is present.

Reactions to the "special medication" zanzalintinib in patients exposed and not exposed to cabozantinib.

Dietary inflammation is associated with the development of urologic cancers.

In health research, the relationship between dietary habits and cancer risks is still a major focus. The has been the subject of a recent meta-analysis.

In infants, laparoscopic robotic pyeloplasty is safe and has a success rate comparable to open surgery.

The results of minimally invasive pyeloplasty (MIP) for the primary cause, ureteropelvic junction obstruction (UPJO), were examined in a recent study.

Recommended News For You

Clinical trial is testing whether heavy lifting could combat cancer side effects

Alternative Medicine for Breast Cancer: Study Raises Concern

Survey shows cancer anxiety has impact well beyond the individual diagnosed

Study finds higher breast cancer rates in areas with more air pollution

Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.

Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma

A new therapeutic approach could help tackle radiation resistance in childhood brain tumors

Recommended Articles For You

A New Hope: How Procarbazine is Revolutionizing Cancer Treatment 

Cancer Staging: Updates, Clinical Insights, and Educational Resources for Medical Professionals 

Liquid Biopsy: A Game-Changer in T-Cell Lymphoma Detection and Management 

Oncolytic Viruses in Breast Cancer: Unlocking Synergy with Novel Combination Therapies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

De-Intensified Therapy Misses Mark in HPV-Positive Oropharyngeal Cancer

2.

Researchers identify a novel biomarker linked to renal cancer recurrence

3.

Breast cancer prevention: How nurse practitioners and physician assistants can help

4.

Surgeons are at higher risk of cancer, study suggests

5.

A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.

1.

Florinef: Understanding Its Uses and Side Effects 

2.

Understanding Adenomyosis: The Role of Ultrasound in Diagnosis Introduction

3.

Omitting Axillary Dissection in Node-Positive Breast Cancer: Insights from the SENOMAC Trial

4.

Surprising Symptoms of Prostate Cancer: What You Need to Know

5.

Unraveling the Mysteries of Coagulopathy: A Comprehensive Definition

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men

2.

Navigating the Complexities of Ph Negative ALL - Part III

3.

The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

5.

Efficient Management of First line ALK-rearranged NSCLC - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot